CN101129971B - Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same - Google Patents
Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same Download PDFInfo
- Publication number
- CN101129971B CN101129971B CN2007101516065A CN200710151606A CN101129971B CN 101129971 B CN101129971 B CN 101129971B CN 2007101516065 A CN2007101516065 A CN 2007101516065A CN 200710151606 A CN200710151606 A CN 200710151606A CN 101129971 B CN101129971 B CN 101129971B
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- chinese medicine
- medicine composition
- rhizoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000003814 drug Substances 0.000 title claims abstract description 83
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 238000000034 method Methods 0.000 title claims abstract description 16
- 208000019255 Menstrual disease Diseases 0.000 title claims description 8
- 229940079593 drug Drugs 0.000 claims abstract description 28
- 241000218176 Corydalis Species 0.000 claims abstract description 16
- 238000002360 preparation method Methods 0.000 claims abstract description 13
- 239000002775 capsule Substances 0.000 claims abstract description 10
- 206010013935 Dysmenorrhoea Diseases 0.000 claims description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 19
- 241001057584 Myrrha Species 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000007788 liquid Substances 0.000 claims description 12
- 239000000796 flavoring agent Substances 0.000 claims description 10
- 235000019634 flavors Nutrition 0.000 claims description 10
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 9
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 9
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 9
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 9
- 239000000052 vinegar Substances 0.000 claims description 9
- 235000021419 vinegar Nutrition 0.000 claims description 9
- 238000001035 drying Methods 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 8
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 claims description 7
- 238000005303 weighing Methods 0.000 claims description 6
- 238000009472 formulation Methods 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 241000545442 Radix Species 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000007796 conventional method Methods 0.000 claims 1
- 230000005906 menstruation Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 4
- 239000002994 raw material Substances 0.000 abstract description 2
- 241001127714 Amomum Species 0.000 abstract 1
- 241000213006 Angelica dahurica Species 0.000 abstract 1
- 241000132012 Atractylodes Species 0.000 abstract 1
- 241000202726 Bupleurum Species 0.000 abstract 1
- 235000008671 Calycanthus floridus Nutrition 0.000 abstract 1
- 235000008670 Calycanthus occidentalis Nutrition 0.000 abstract 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 240000007311 Commiphora myrrha Species 0.000 abstract 1
- 235000006965 Commiphora myrrha Nutrition 0.000 abstract 1
- 244000075634 Cyperus rotundus Species 0.000 abstract 1
- 241000123589 Dipsacus Species 0.000 abstract 1
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract 1
- 235000017443 Hedysarum boreale Nutrition 0.000 abstract 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 abstract 1
- 244000148992 Lindera benzoin Species 0.000 abstract 1
- 235000004520 Lindera benzoin Nutrition 0.000 abstract 1
- 235000008262 Lindera benzoin var. benzoin Nutrition 0.000 abstract 1
- 235000007265 Myrrhis odorata Nutrition 0.000 abstract 1
- 244000236658 Paeonia lactiflora Species 0.000 abstract 1
- 235000008598 Paeonia lactiflora Nutrition 0.000 abstract 1
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 235000017803 cinnamon Nutrition 0.000 abstract 1
- 235000013399 edible fruits Nutrition 0.000 abstract 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 19
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 15
- 101800000989 Oxytocin Proteins 0.000 description 15
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 description 15
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 15
- 229960001723 oxytocin Drugs 0.000 description 15
- 210000004291 uterus Anatomy 0.000 description 14
- 239000000047 product Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 208000005171 Dysmenorrhea Diseases 0.000 description 11
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 208000002193 Pain Diseases 0.000 description 6
- 230000000202 analgesic effect Effects 0.000 description 6
- 230000036407 pain Effects 0.000 description 6
- 230000001105 regulatory effect Effects 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 230000003285 pharmacodynamic effect Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 231100000331 toxic Toxicity 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 229960000583 acetic acid Drugs 0.000 description 3
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 3
- 238000011047 acute toxicity test Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000000857 drug effect Effects 0.000 description 3
- 230000005284 excitation Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- -1 mixing is granulated Substances 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010039897 Sedation Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 230000036592 analgesia Effects 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000151 deposition Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000003292 glue Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 206010025482 malaise Diseases 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000012567 medical material Substances 0.000 description 2
- 239000002547 new drug Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000036280 sedation Effects 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 101001031591 Mus musculus Heart- and neural crest derivatives-expressed protein 2 Proteins 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 description 1
- 229960000452 diethylstilbestrol Drugs 0.000 description 1
- 206010013663 drug dependence Diseases 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- 230000027758 ovulation cycle Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 210000004994 reproductive system Anatomy 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000041 toxicology testing Toxicity 0.000 description 1
- 230000013948 uterine smooth muscle contraction Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a Chinese medicinal composition for treating women's primary dysmenorrheal or abnormal menstruation and its preparing process, wherein the medicinal composition is prepared from the following raw materials (by weight portion): bupleurum root 12-13 parts, Chinese angelica root 12-13 parts, white peony root 12-13 parts, corydalis tuber 12-13 parts, nutgrass flatsedge rhizome 12-13 parts, spicebush root 10-11 parts, white atractylodes rhizome 5-6 parts, licorice root 5-6 parts, myrrh 5-6 parts, cinnamon 5-6 parts, amomum fruit 3-4 parts and dipsacus root 4-5 parts. The medicament can be prepared through the conventional drug making processes, and the dose form can be any one of the clinically suitable oral administration preparations, preferably capsules.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition, relate in particular to a kind of Chinese medicine composition for the treatment of dysmenorrhes or menoxenia and preparation method thereof, belong to the field of Chinese medicines.
Background technology
According to statistics, China women of child-bearing age account for 1/4th of population, be about 34,185 ten thousand people, calculate by the minimum sickness rate 33.19% of dysmenorrhea, dysmenorrhea patient is about 11,346 ten thousand people, certain transnational survey institute shows coastal 17 large-and-medium size cities of China result that investigates: the annual capacity in China regulating menstruation market is 5,100,000,000 yuan, and wherein this plate of dysmenorrhea has occupied most market shares.The investigation data shows, the crowd who the pain related symptoms is arranged and take the menstruction regulating and pain relieving product accounts for 40%, and the crowd who does not take the menstruction regulating and pain relieving series products is 43%.
Along with the raising day by day to self health concerns degree of the reform of China's Health care system and female consumer, the market of gynecological's quasi drugs sharply enlarges.But because of consumer to the information attention of dysmenorrhea series products not initiatively, the exploitation degree of dysmenorrhea series products is not high at present.Western medicine mostly is the anti-inflammatory analgetic class, and side effect is big, is in a disadvantageous position in market sale.Chinese medicine has that property of medicine gentleness, side effect are little, the characteristics for the treatment of both the principal and secondary aspects of a disease, the status that is in a leading position in the selling market.
This shows that dysmenorrhea market exists very big potentiality, particularly in women medicine kind, focus mostly on enrich blood, the looks improving and the skin nourishing field, the regulating menstruation product is also few, and Chinese patent medicine regulating menstruation class is particularly treated the product of the class of primary dysmenorrhea and made a new start very few.
At present, YUEYUESHU board TONGJINGBAO KELI is enjoyed quite high reputation and popularity in female consumer, and the coverage rate of domestic market is 98%, and the comprehensive market occupation rate reaches 11.98%.This drug main will be made by Radix Angelicae Sinensis, Cortex Cinnamomi, Flos Carthami, Radix Salviae Miltiorrhizae, Rhizoma Corydalis, Oletum Trogopterori, rhizoma sparganic, Rhizoma Curcumae and the Radix Aucklandiae, for dysmenorrhes, menoxenia, chronic basin glue inflammation etc. has certain curative effect, but because this official ceremonial dress is longer with the time, and dosage is big, and consumer can disposablely not buy, and can select single box to buy, thereby purchase frequency is higher in a short time, consumer more wish to buy carry, taking convenience, taking dose is little, toxic and side effects is little, the product for the treatment of both the principal and secondary aspects of a disease.
At present, the treatment dysmenorrhea is abroad mainly based on chemical medicine, and domestic Chinese medicine has occupied about 50% the market share.But the new drug development cycle based on chemosynthesis is long, success rate is low, difficulty is big, expense is high, and toxic and side effects is bigger, medicine source property illness is increasing, be easy to generate Drug resistance and drug dependence, some worldwide difficult and complicated illness are seemed unable to do what one wishes, new drug (NEC) cost increases, costs an arm and a leg in addition, the benefit phase is short, causes western medicine and medical practitioners more and more can not satisfy the human health demand fully, forces people to produce the strong desire of " back to nature "; On the other hand, because the improvement of living condition, living environment improves day by day to the requirement of drug effectiveness, safety, " back to nature " become a kind of certainty of social development, and the research and development natural drug has become the new trend of current international medical science development.
Primary dysmenorrhea is meant and can not find the obvious pathological changes of reproductive system, but dysmenorrhea former because of some thereby that cause takes place, and primary dysmenorrhea is most commonly in the unmarried women colony that does not produce below 25 years old.In recent years, report that abroad women's sickness rate of primary dysmenorrhea before 19 years old obviously increases.The Chinese medicine medicine for the treatment of primary dysmenorrhea in the market is few, and curative effect is very indefinite
Summary of the invention
The present invention's technical problem at first to be solved is to overcome the deficiencies in the prior art, a kind of effectively Chinese medicine composition of menstruction regulating and pain relieving is provided, dysmenorrhea can effectively be treated or control to this Chinese medicine composition, has advantages such as toxic and side effects is little, clinical practice safety, convenience.
The present invention's technical problem at first to be solved is achieved through the following technical solutions:
A kind of Chinese medicine composition for the treatment of primary dysmenorrhea, menoxenia is mainly made by following bulk drugs: Radix Bupleuri 12-13 part, Radix Angelicae Sinensis 12-13 part, Radix Paeoniae Alba 12-13 part, Rhizoma Corydalis 12-13 part, Rhizoma Cyperi 12-13 part, Radix Linderae 10-11 part, Rhizoma Atractylodis Macrocephalae 5-6 part, Radix Glycyrrhizae 5-6 part, Myrrha 5-6 part, Cortex Cinnamomi 5-6 part, Fructus Amomi 3-4 part and Radix Dipsaci 4-5 part;
Preferably, the weight portion of each crude drug is: 4.5 parts of 12.5 parts of Radix Bupleuri, 12.5 parts of Radix Angelicae Sinensis, 12.5 parts of the Radix Paeoniae Albas, 12.5 parts of Rhizoma Corydalis, 12.5 parts of Rhizoma Cyperis, 10.5 parts of the Radixs Linderae, 5.5 parts of the Rhizoma Atractylodis Macrocephalaes, 5.5 parts in Radix Glycyrrhizae, 5.5 parts of Myrrhas, 5.5 parts of Cortex Cinnamomis, 3.5 parts of Fructus Amomis and Radix Dipsacis.
In order to reach better therapeutic effect, described Rhizoma Corydalis, Rhizoma Cyperi and Myrrha are preferably Rhizoma Corydalis (processed with vinegar), Rhizoma Cyperi (processed with vinegar) and the Myrrha (processed with vinegar) through concocting; The described Rhizoma Atractylodis Macrocephalae is preferably the Rhizoma Atractylodis Macrocephalae (parched) through concocting.The concocting method of above-mentioned raw materials medicine can be carried out according to the disclosed method of " Chinese medicine voluminous dictionary " (Shanghai science tech publishing house).
Used each crude drug of the present invention all can be bought from common pharmacy and obtain, and its specification meets national medical standard.
The present invention is according to traditional theory of Chinese medical science, 12 flavor pure natural medicals such as Radix Bupleuri have been selected for use, process through extraction, natural Chinese medicinal herb has drug effect gentleness, conditioning functions is strong and toxic and side effects is low advantage, by the pharmaceutical composition that natural drug is formed, its overall therapeutic effect is more stable and lasting.
Prove that according to the pharmacological research data Chinese medicine composition of the present invention is except that protecting the liver, the antiinflammatory, analgesia, sedation, the animal uterus smooth muscle being had lax and suppresses the effect of its tension force and motion.The pharmacological research data of single medicinal material shows, Radix Bupleuri, Radix Paeoniae, Rhizoma Corydalis, Myrrha, Rhizoma Cyperi all have analgesia, sedation, wherein Radix Paeoniae, Rhizoma Cyperi, Radix Angelicae Sinensis have stronger spasmolysis to the animal smooth muscle, and these all are the pharmacodynamics bases that Chinese medicine composition of the present invention can be treated dysmenorrhea.
Medicine activity component of the present invention can add various adjuvants required when preparing different dosage form, for example disintegrating agent, lubricant, adhesive etc., method of Chinese medicinal with routine is prepared into any oral formulations commonly used, can be pill, capsule, tablet, powder, granule or oral liquid etc. for example, be preferably capsule.
Preferably, a kind of method for preparing Chinese medicine composition of the present invention may further comprise the steps:
(1) takes by weighing each crude drug by following weight: Radix Bupleuri 12-13 part, Radix Angelicae Sinensis 12-13 part, Radix Paeoniae Alba 12-13 part, Rhizoma Corydalis 12-13 part, Rhizoma Cyperi 12-13 part, Radix Linderae 10-11 part, Rhizoma Atractylodis Macrocephalae 5-6 part, Radix Glycyrrhizae 5-6 part, Myrrha 5-6 part, Cortex Cinnamomi 5-6 part, Fructus Amomi 3-4 part and Radix Dipsaci 4-5 part;
(2) above-mentioned 12 flavor crude drug are decocted with water, decoction liquor filters, and filtrate is concentrated into thick paste, adds microcrystalline Cellulose, mixing, and drying under reduced pressure is pulverized, and sieves, and mixing is granulated, promptly.
In the step (2), preferred, 12 flavor crude drug are added 8 times of weight water logging bubbles 2 hours, decoct again 3 times, decocted 2 hours at every turn;
In the step (2), preferably, filtrate is concentrated into the thick paste of relative density 1.20～1.24 (80～85 ℃);
In the step (2), the temperature of described drying under reduced pressure is 60 ℃.
Pharmacy before clinical, pharmacology, toxicological study, Chinese medicine composition preparation technology of the present invention is reasonable, steady quality, controlled.
Pharmacodynamics test proves that this medicine has very strong analgesic activity, and there are very strong inhibition and spasmolysis in the uterus, for the treatment dysmenorrhea provides strong pharmacological basis.
Chinese medicine composition of the present invention and YUEYUESHU have been carried out pharmacodynamics relatively, and the result shows that the analgesic effect of Chinese medicine composition 6g/kg of the present invention and YUEYUESHU 25g/kg is close, but dosage differs 4 times more than.Chinese medicine composition dosage 2% * 1ml energy all-out confrontation oxytocin of the present invention is to the excitation of rat uterus, the frequency, amplitude, energy of uterine activity all significantly reduced, P＜0.01～0.001, and YUEYUESHU dosage 30% * 1ml only can reduce amplitude, P＜0.05 in the excited uterus of oxytocin.Its active frequency, energy there is not the P of influence＜0.05; So Chinese medicine composition of the present invention has possessed the characteristics that therapeutic effect is good, taking dose is little.
Chinese medicine composition acute toxicity test of the present invention shows, mouse gavaging Chinese medicine composition one twice-daily of the present invention, and total dose was 300g/kg on 1st, observing did not have deadly in 7 days, and maximum tolerated dose 300g/kg is 625 times of adult's dosage, illustrate that Chinese medicine composition toxicity of the present invention is very little, drug safety.
Chinese medicine composition of the present invention is a pure Chinese medicinal preparation, does not contain toxicity medical material and non-official remedy material in the prescription, can effectively treat primary dysmenorrhea.The clinical soreness of waist pain pain that is applicable to, fatigue and weakness, on the low side through measuring after advanced menstruation or the mistake, menses are purple dark or blood stasis piece etc. arranged.For menoxenia, chronic basin glue inflammation etc. all has significant curative effect.
Usage and consumption: the dosage of medicine of the present invention depends on concrete dosage form, and factor such as age of patient, body weight, health status.As guidance: capsule, oral at every turn (taking after mixing it with water) 3-6g (4) that is grown up, every day 2～3 (3) is inferior; Menstruation the last week continues to menstruation and ends in back 3 days, serve on 3 menstrual cycle.
The specific embodiment
Further describe the present invention by the following examples, it should be understood that these embodiment only are used for the purpose of illustration, never limit protection scope of the present invention.
The preparation of embodiment 1 capsule
Take by weighing each crude drug (unit: g): Radix Bupleuri 12, Radix Angelicae Sinensis 12, the Radix Paeoniae Alba 12, Rhizoma Corydalis (vinegar system) 12, Rhizoma Cyperi (vinegar system) 12, the Radix Linderae 10, the Rhizoma Atractylodis Macrocephalae (stir-fry) 5, Radix Glycyrrhizae 5, Myrrha (vinegar system) 5, Cortex Cinnamomi 5, Fructus Amomi 3, Radix Dipsaci 4 by following weight;
Above-mentioned 12 flavor crude drug add 8 times of weight water logging bubbles 2 hours, decoct 3 times, decoct 2 hours at every turn; Merge decoction liquor, filter, filtrate is concentrated into the thick paste of relative density 1.20～1.24 (80～85 ℃), and it is an amount of to add microcrystalline Cellulose, mixing, drying under reduced pressure (60 ℃) is pulverized, and sieves, and it is an amount of to add microcrystalline Cellulose again, sieves, add magnesium stearate, mixing is granulated, and is encapsulated, promptly.
The preparation of embodiment 2 granules
Take by weighing each crude drug (unit: g): Radix Bupleuri 13, Radix Angelicae Sinensis 13, the Radix Paeoniae Alba 13, Rhizoma Corydalis 13, Rhizoma Cyperi 13, the Radix Linderae 11, the Rhizoma Atractylodis Macrocephalae 6, Radix Glycyrrhizae 6, Myrrha 6, Cortex Cinnamomi 6, Fructus Amomi 4, Radix Dipsaci 5 by following weight;
Above-mentioned 12 flavor crude drug add 10 times of weight water logging bubbles 2 hours, decoct 2 times, decoct 2 hours at every turn; Merge decoction liquor, filter, filtrate is concentrated into the thick paste of relative density 1.20～1.24 (80～85 ℃), and it is an amount of to add microcrystalline Cellulose, mixing, drying under reduced pressure (60 ℃) is pulverized, and sieves, and it is an amount of to add microcrystalline Cellulose again, sieves, add magnesium stearate, mixing is granulated, promptly.
The preparation of embodiment 3 tablets
Take by weighing each crude drug (unit: g): Radix Bupleuri 12.5, Radix Angelicae Sinensis 12.5, the Radix Paeoniae Alba 12.5, Rhizoma Corydalis 12.5, Rhizoma Cyperi 12.5, the Radix Linderae 10.5, the Rhizoma Atractylodis Macrocephalae 5.5, Radix Glycyrrhizae 5.5, Myrrha 5.5, Cortex Cinnamomi 5.5, Fructus Amomi 3.5, Radix Dipsaci 4.5 by following weight;
Above-mentioned 12 flavor crude drug add 8 times of weight water logging bubbles 3 hours, decoct 3 times, decoct 2 hours at every turn; Merge decoction liquor, filter, filtrate is concentrated into the thick paste of relative density 1.20～1.24 (80～85 ℃), and it is an amount of to add microcrystalline Cellulose, mixing, drying under reduced pressure (60 ℃), pulverize, sieve, it is an amount of to add microcrystalline Cellulose again, sieves, and adds magnesium stearate, mixing is granulated, granulate, and tabletting, promptly.
The optimum preparation condition test of test example 1 Chinese medicine composition of the present invention
One, decocting part technology
(1) test 1: with the medical material Radix Angelicae Sinensis, Rhizoma Cyperi, Cortex Cinnamomi, Fructus Amomi that contain volatile oil in the Chinese medicine composition of the present invention totally four kinds extract volatile oil, gained volatile oil is mixed with all the other 8 herbal medicine water decoction extracts, must product 1 (volatile oil is with decoct);
Test 2: with 12 in the Chinese medicine composition of the present invention flavor crude drug all carry out decocting boil extract obtained, product 2 (water decoction).
Test 3:
To test 1 and test 2 resulting products 1 and 2 carry out drug effect, acute toxicity test relatively.The result shows, mice acetic acid is brought out writhing test, and both do not have significant difference (P＞0.05); And product 1 toxicity strengthens, and 22 mices (total dose 300g/kg on the one) have 7 death, and none example of product 2 (total dose 300g/kg on the one) is dead.
(2) medicine 60% concentration of alcohol alcohol deposition method gained preparation of the present invention and product 2 (water decoction) are carried out drug effect, acute toxicity test relatively, both do not have significant difference (P＞0.05) as a result.Though the extract obtained weight of alcohol deposition method only is water decoction 1/2,, adopt the water decoction extraction and preparation technique comparatively suitable from curative effect and cost consideration.
Among the preparation technology decocting is boiled number of times, time and amount of water and carry out positive quadraturing design test, the result decocts 3 times, and each 2 hours, amount of water was an optimum process condition for 8 times.The required ratio of adjuvant of capsule is also carried out positive quadraturing design test, and starch 40g, magnesium stearate 3g are best proportioning.
Test example 2 Chinese medicine compositions of the present invention and compare with the YUEYUESHU pharmacodynamics
One, Chinese medicine composition of the present invention and YUEYUESHU board TONGJINGBAO KELI single administration Dichlorodiphenyl Acetate bring out the mouse writhing experiment relatively:
Female 45 the 18～22g of mice divide equally 3 groups by body weight, 15 every group.Each group is gastric infusion respectively, blank (water) 30g/kg, confession reagent thing (Chinese medicine composition of the present invention, the capsule that embodiment 1 is prepared) 6g/kg, YUEYUESHU board TONGJINGBAO KELI (as if the western Pharmacy stock Co., Ltd in Henan produces) 25g/kg, irritated behind the stomach 1 hour, lumbar injection 0.6% acetic acid 0.2ml/ only, the observation mice was turned round the body number in 20 minutes, and experimental result sees Table 1
Table 1 brings out the analgesic activity of mouse writhing experiment for reagent thing and YUEYUESHU board TONGJINGBAO KELI single administration Dichlorodiphenyl Acetate
| Group | Dosage g/kg | Number of animals (only) | Take ip0.6% glacial acetic acid after 1 hour | |
| Turned round the body number of times in 20 minutes | Suppression ratio (%) | |||
| Contrast (water) | 30 | 15 | 40.80 | |
| YUEYUESHU | 25 | 15 | 17.00 | 58.33 |
| For the reagent thing | 6 | 15 | 16.07 | 60.61 |
By above result as seen, compare with matched group (water) for reagent thing, YUEYUESHU board TONGJINGBAO KELI, by statistics the equal highly significant of both analgesic activities (P＜0.001).And YUEYUESHU board TONGJINGBAO KELI 25g/kg and confession reagent thing 6g/kg effect close (P＜0.05).But both compare by taking dose, and are littler 4 times more than than YUEYUESHU board TONGJINGBAO KELI dosage for the reagent thing.
Two, Chinese medicine composition of the present invention and YUEYUESHU board TONGJINGBAO KELI compare the influence of isolated uterine smooth muscle
Method: the same; rat is injected diethylstilbestrol in advance; but the uterus of taking off is put in the Rockwell liquid, makes the uterus inactive, traces one section normal activity after static 15 minutes and adds oxytocin 0.01u/ml0.04～0.08 again trace 30 minutes in 40ml Rockwell liquid.When selecting the oxytocin effect to reach the peak in 10 minutes, add Rockwell liquid 1ml respectively, supply reagent thing (Chinese medicine composition of the present invention, the capsule that embodiment 1 is prepared) 2% * 1ml, YUEYUESHU board TONGJINGBAO KELI 30% * 1ml relatively supplies the effect to oxytocin of reagent thing, YUEYUESHU board TONGJINGBAO KELI.
Table 2 is for the influence to uterine smooth muscle contraction frequency due to the oxytocin of reagent thing and YUEYUESHU board TONGJINGBAO KELI
| Group | The uterus number | Give behind the oxytocin frequency time/10 minutes (X ± SD) | Give the variation (X ± SD) of frequency behind Rockwell liquid or the medicine | |
| Preceding 10 gradation/10 minutes (± %) | Back 10 gradation/10 minutes (± %) | |||
| Rockwell liquid | 6 | 7.33±2.88 | 6.83±2.48 (+3.60±45.88) | 5.33±2.42 (-22.46±31.62) |
| For reagent thing (2% * 1ml) | 7 | 9.14±0.90 | 4.92±2.21 (-54.13±22.33) | 2.29±2.06 (-75.83±21.52)※※ △△ |
| YUEYUESHU (30% * 1ml) | 7 | 8.71±1.89 | 6.29±1.25 (-26.07±17.18) | 5.29±1.38 (-37.42±20.83) |
Annotate: 1, driving in the pipe is 40ml Rockwell liquid
2, with the matched group ratio
*P＜0.05
*P＜0.01
3, for reagent thing and YUEYUESHU board TONGJINGBAO KELI than △ P＜0.05 △ △ P＜0.01;
Table 3 is for the influence to uterine smooth muscle shrinkage amplitude due to the oxytocin of reagent thing and YUEYUESHU board TONGJINGBAO KELI
| Group | Uterus number (individual) | Gave amplitude behind the oxytocin (X ± SDnm)/10 minute | Variation (X ± SDnm/10 branch) to amplitude behind Rockwell liquid or the medicine | |
| Preceding 10 minutes nm/10 branches (± %) | The 10 fens nm/10 branches in back (± %) | |||
| Rockwell liquid | 6 | 36.41±20.30 | 47.51±24.07 (36.72±42.66) | 49.42±18.79 (46.98±33.86) |
| For reagent thing (2% * 1ml) | 7 | 56.51±15.36 | 57.96±16.15 (+2.37±7.72) | 23.47±18.29△△△ (-59.16±29.09)*** |
| YUEYUESHU (30% * 1ml) | 7 | 56.92±12.69 | 63.55±16.86 (+11.36±17.35) | 64.83±14.49 (+14.63±14.63)* |
Annotate: 1, with the matched group ratio
*P＜0.05
* *P＜0.001
2, for reagent thing and YUEYUESHU board TONGJINGBAO KELI than △ △ △ P＜0.001
Table 4 is for the influence to uterine motility (frequency * amplitude) due to the oxytocin of reagent thing and YUEYUESHU board TONGJINGBAO KELI
| Group | Uterus number (individual) | Give behind the oxytocin energy/10 minute (X ± SD) | Give the variation (X ± SD) of energy behind Rockwell liquid or the medicine | |
| Energy/10 minute (± %) | Energy/10 minute (± %) | |||
| Rockwell liquid | 6 | 256.32±184.34 | 311.35±158.34 (+48.10±92.54) | 252.34±119.41 (+20.41±75.42) |
| For reagent thing (2% * 1ml) | 7 | 516.57±137.66 | 242.71±139.85△ (-53.49±21.11) | 68.29±79.97△△△ (-87.72±13.58)** |
| YUEYUESHU (30% * 1ml) | 7 | 504.71±181.95 | 404.58±156.66 (-16.69±29.26) | 349.85±142.79 (-26.98±31.53)* |
Annotate: 1, with the matched group ratio
*P＜0.05
*P＜0.01
2, for reagent thing and YUEYUESHU board TONGJINGBAO KELI than △ P＜0.05 △ △ △ P＜0.001; The result shows, (2% * 1ml) can resist the excitation in oxytocin uterus for the reagent thing, uterus frequency, amplitude, energy are reduced, the effect highly significant (P＜0.01-0.001), and YUEYUESHU board TONGJINGBAO KELI (30% * 1ml) only can reduce the amplitude (P＜0.05) in the excited uterus of oxytocin, and though frequency and energy are slightly reduced, add up not remarkable.For the reagent thing (2% * 1ml) with YUEYUESHU board TONGJINGBAO KELI (30% * 1ml) effect compare both differences very, highly significant (P＜0.001).
Conclusion: close by above two analgesic activities that experiment showed, confession reagent thing 6g/kg and YUEYUESHU board TONGJINGBAO KELI 25g/kg, but littler more than 4 times for reagent thing taking dose than YUEYUESHU.For reagent thing 2% * 1ml can the all-out confrontation oxytocin to the excitation in uterus, make frequency, amplitude, energy significantly reduce (P＜0.01-0.001); And YUEYUESHU board TONGJINGBAO KELI 30% * 1ml only can reduce amplitude P＜0.05 in the excited uterus of oxytocin.Both compare by statistics difference very, highly significant P＜0.001.
Claims (9)
1. a Chinese medicine composition for the treatment of primary dysmenorrhea, menoxenia is characterized in that, is made in accordance with the following methods by following bulk drugs:
(1) takes by weighing each crude drug by following weight: Radix Bupleuri 12-13 part, Radix Angelicae Sinensis 12-13 part, Radix Paeoniae Alba 12-13 part, Rhizoma Corydalis 12-13 part, Rhizoma Cyperi 12-13 part, Radix Linderae 10-11 part, Rhizoma Atractylodis Macrocephalae 5-6 part, Radix Glycyrrhizae 5-6 part, Myrrha 5-6 part, Cortex Cinnamomi 5-6 part, Fructus Amomi 3-4 part and Radix Dipsaci 4-5 part;
(2) above-mentioned 12 flavor crude drug are decocted with water, decoction liquor filters, and filtrate is concentrated into thick paste, adds microcrystalline Cellulose, mixing, and drying under reduced pressure is pulverized, and sieves, and mixing is granulated, promptly;
Wherein said Rhizoma Corydalis, Rhizoma Cyperi and Myrrha are Rhizoma Corydalis (processed with vinegar), Rhizoma Cyperi (processed with vinegar) and Myrrha (processed with vinegar) through concocting.
2. according to the Chinese medicine composition of claim 1, it is characterized in that the weight portion of each crude drug is: 12.5 parts of Radix Bupleuri, 12.5 parts of Radix Angelicae Sinensis, 12.5 parts of the Radix Paeoniae Albas, 12.5 parts of Rhizoma Corydalis, 12.5 parts of Rhizoma Cyperis, 10.5 parts of the Radixs Linderae, 5.5 parts of the Rhizoma Atractylodis Macrocephalaes, 5.5 parts in Radix Glycyrrhizae, 5.5 parts of Myrrhas, 5.5 parts of Cortex Cinnamomis, 3.5 parts of Fructus Amomis, 4.5 parts of Radix Dipsacis.
3. according to the Chinese medicine composition of claim 1 or 2, it is characterized in that: be prepared into oral formulations according to conventional method of Chinese medicinal.
4. according to the Chinese medicine composition of claim 3, it is characterized in that: described oral formulations is pill, capsule, tablet, powder, granule or oral liquid.
5. according to the Chinese medicine composition of claim 4, it is characterized in that: described oral formulations is a capsule.
6. method for preparing the described Chinese medicine composition of claim 1 comprises:
(1) takes by weighing each crude drug by following weight: Radix Bupleuri 12-13 part, Radix Angelicae Sinensis 12-13 part, Radix Paeoniae Alba 12-13 part, Rhizoma Corydalis 12-13 part, Rhizoma Cyperi 12-13 part, Radix Linderae 10-11 part, Rhizoma Atractylodis Macrocephalae 5-6 part, Radix Glycyrrhizae 5-6 part, Myrrha 5-6 part, Cortex Cinnamomi 5-6 part, Fructus Amomi 3-4 part and Radix Dipsaci 4-5 part;
(2) above-mentioned 12 flavor crude drug are decocted with water, decoction liquor filters, and filtrate is concentrated into thick paste, adds microcrystalline Cellulose, mixing, and drying under reduced pressure is pulverized, and sieves, and mixing is granulated, promptly.
7, according to the method for claim 6, it is characterized in that: in the step (2) 12 flavor crude drug are added 8 times of weight water logging bubbles 2 hours, decoct again 3 times, decocted 2 hours at every turn.
8. according to the method for claim 6, it is characterized in that: the thick paste that in the step (2) filtrate to be concentrated into 80～85 ℃ of mensuration are relative densities 1.20～1.24.
9. according to the method for claim 6, it is characterized in that: the temperature of the drying under reduced pressure described in the step (2) is 60 ℃.
10. claim 1 or 2 the Chinese medicine composition purposes in the medicine of preparation treatment primary dysmenorrhea, menoxenia.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101516065A CN101129971B (en) | 2007-09-25 | 2007-09-25 | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007101516065A CN101129971B (en) | 2007-09-25 | 2007-09-25 | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101129971A CN101129971A (en) | 2008-02-27 |
| CN101129971B true CN101129971B (en) | 2010-11-24 |
Family
ID=39127483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007101516065A Expired - Fee Related CN101129971B (en) | 2007-09-25 | 2007-09-25 | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101129971B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105194396A (en) * | 2013-07-31 | 2015-12-30 | 朱保生 | Traditional Chinese medicine composition for treating irregular menstruation |
| CN103655940B (en) * | 2013-12-05 | 2016-08-17 | 陕西东科制药有限责任公司 | A kind of Chinese medicine compound treating menopathy |
| CN104667249B (en) * | 2015-03-23 | 2017-11-21 | 张晓辉 | A kind of Chinese medicine composition for treating primary dysmenorrhea |
| CN105935402A (en) * | 2016-05-06 | 2016-09-14 | 许美凤 | Traditional Chinese medicinal composition for treating abnormal menstruation |
| CN113332404A (en) * | 2021-07-13 | 2021-09-03 | 刘中平 | Traditional Chinese medicine composition for regulating menstruation and stopping leukorrhagia |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179327A (en) * | 1997-11-13 | 1998-04-22 | 王汝辉 | Medicine for treating woman's dysmenorrhea and preparing process thereof |
| CN1742993A (en) * | 2005-09-26 | 2006-03-08 | 四川泰华堂制药有限公司 | Chinese patent medicine for treating gynaecologic disease and preparing method |
-
2007
- 2007-09-25 CN CN2007101516065A patent/CN101129971B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1179327A (en) * | 1997-11-13 | 1998-04-22 | 王汝辉 | Medicine for treating woman's dysmenorrhea and preparing process thereof |
| CN1742993A (en) * | 2005-09-26 | 2006-03-08 | 四川泰华堂制药有限公司 | Chinese patent medicine for treating gynaecologic disease and preparing method |
Non-Patent Citations (4)
| Title |
|---|
| 李莉等.月痛安胶囊治疗原发性痛经的临床观察.湖北中医杂志29 1.2007,29(1),37-38. |
| 李莉等.月痛安胶囊治疗原发性痛经的临床观察.湖北中医杂志29 1.2007,29(1),37-38. * |
| 王胜春等.当归 莪术 延胡索及其配伍对小鼠的毒性反应.时珍国医国药15 4.2004,15(4),211-213. |
| 王胜春等.当归 莪术 延胡索及其配伍对小鼠的毒性反应.时珍国医国药15 4.2004,15(4),211-213. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101129971A (en) | 2008-02-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101239112B (en) | Chinese medicinal composition for regulating blood fat and preparation thereof | |
| CN102670961B (en) | Traditional Chinese medicine for treating middle and old aged habitual constipation | |
| CN104338062A (en) | Chinese medicinal preparation for treating stomachache and diarrhea | |
| CN104027529A (en) | Traditional Chinese medicine composition for regulating blood lipids, blood pressure and blood glucose and preparation method thereof | |
| Musthaba et al. | Patented herbal formulations and their therapeutic applications | |
| CN101129971B (en) | Traditional Chinese medicine composition for treating women's menorrhalgia and menoxenia, and method of preparing the same | |
| CN102935133B (en) | Traditional Chinese medicine composition for treating rheumatic arthritis as well as preparation method and application thereof | |
| CN101485870A (en) | Medicament for promoting digestion and expelling intestinal parasites | |
| CN102198175B (en) | Chinese medicine composition | |
| CN101664533B (en) | Chinese medicament for treating acute and chronic mammary hyperplasia and preparation method | |
| CN101664541B (en) | Medicament for treating dysmenorrhoea and preparation method thereof | |
| CN102908403A (en) | Chinese materia medica preparation for treating gout and preparation method thereof | |
| CN102895620A (en) | Preparation technology and production method for integrated new formulation of licorice heart-draining decoction | |
| CN104056177A (en) | Traditional Chinese medicine composition for treating otitis media | |
| CN100515462C (en) | Chinese medicine for treating cardiovascular and cerebrovascular trrombus and preparing method | |
| CN101357187A (en) | Medicine for treating the prostatitis | |
| CN105362630A (en) | Climacteric syndrome treatment pharmaceutical composition and preparation method thereof | |
| CN1311849C (en) | Medicinal composition for treating swelling paint | |
| CN103520684A (en) | Traditional Chinese medicine compound for reducing blood sugar | |
| CN103705868B (en) | One treats hyperthyroid pharmaceutical composition and application thereof | |
| CN102133274A (en) | Chinese medicinal composition | |
| CN103751239B (en) | A kind of preparation method and applications of Radix Et Caulis Acanthopanacis Senticosi total glucosides and manyprickle acanthopanax general glycosides formulation | |
| CN103301380A (en) | Liver-soothing and qi-regulating traditional Chinese medicinal composition and preparation method thereof | |
| CN100411670C (en) | Medicine for treating tumor in upper digestive tract and its preparing method | |
| CN102824446B (en) | Medicinal composition with anti-fatigue effect as well as preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: JILIN YIMINGTANG PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: XU YOUZHANG Effective date: 20110325 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20110325 Address after: 136001 No. 3288, development zone, Siping City, Jilin Patentee after: Yimintang Pharm. Co., Ltd., Jilin Address before: 136001 No. 3288, development zone, Siping City, Jilin Patentee before: Xu Youzhang |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101124 Termination date: 20160925 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |